Bayer AG and Kumquat Biosciences Inc. have entered into an exclusive global license and collaboration agreement to develop and commercialize Kumquat’s KRAS G12D inhibitor.
With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with a global deal that could bring Kumquat Biosciences Inc. up to $1.3 billion in payments.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Kumquat Biosciences Inc. has identified GTPase KRAS and KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer, particularly solid tumors and hematological cancer.
Kumquat Biosciences Inc. has synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Kumquat Biosciences Inc. has described heterocyclic compounds and PROTACs acting as GTPase KRAS (G12D, G12C, G12S and G13D mutant), and/or G12V and wild-type GTPase KRAS inhibitors reported to be useful for the treatment of cancer.
Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.
Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
